SCH-442,416 je visoko selektivan antagonistadenozinskogA2a receptora. On je u širokoj upotrebi u Njegovoj 11C radioobeleženoj formi za mapiranje distribucije A2a receptora u mozgu.[5] Uzimajući u obzir distribuciju A2a receptora u mozgu, oni su istraživani za tretman raznih neuroloških poremećaja, i utvrđeno je da SCH-442,416 potencijalno može da nađe primenu u tretmanu depresije,[6]Parkinsonove bolesti,[7] i katalepsije.[8]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Apr;32(4):405-13. PMID15549298
↑El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003 Dec 9;61(11 Suppl 6):S82-7. PMID14663017
↑Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, Noda A, Nagai T, Mizoguchi H, Nishimura S, Yamada K. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. Journal of Pharmacological Sciences. 2007 Mar;103(3):329-32. PMID17341841
↑Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, Matsuya T, Miyoshi S, Nishimura S, Matsuoka N. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. Journal of Nuclear Medicine. 2008 Jul;49(7):1183-8. PMID18552135